Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function

被引：2
|
作者：
Sise, Meghan E. [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Div Nephrol, 165 Cambridge St,Suite 302, Boston, MA 02114 USA
来源：
KIDNEY INTERNATIONAL REPORTS | 2019年 / 4卷 / 02期
基金：
美国国家卫生研究院;
关键词：
DISEASE;
D O I：
10.1016/j.ekir.2018.11.018
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：191 / 193
页数：3
相关论文
共 50 条
  • [1] Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection
    Cheng, Elaine Y.
    Saab, Sammy
    Holt, Curtis D.
    Busuttil, Ronald W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2835 - 2848
  • [2] Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection
    Klibanov, Olga M.
    Gale, Stormi E.
    Santevecchi, Barbara
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (05) : 566 - 581
  • [3] Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients
    Tosun, Guven Gurkan
    Sultanova, Fidan
    Nihan, A. K.
    Hizel, Kenan
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2019, 8
  • [4] Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
    Danis, Nilay
    Toz, Huseyin
    Unal, Nalan
    Yilmaz, Mumtaz
    Turan, Ilker
    Gunsar, Fulya
    Karasu, Zeki
    Ersoz, Galip
    Ozkahya, Mehmet
    Akarca, Ulus Salih
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (08): : 695 - 701
  • [5] ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection
    Leung, D. H.
    Yao, B.
    Viani, R. M.
    Gonzalez-Peralta, R. P.
    Jonas, M. M.
    Lobritto, S. J.
    Narkewicz, M. R.
    Sokal, E.
    Fortuny, C.
    Hsu, E.
    Wirth, S.
    Del Valle-Segarra, A.
    Zha, J.
    Larsen, L.
    Liu, L.
    Shuster, D. L.
    Cohen, D. E.
    Rosenthal, P.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S300 - S301
  • [6] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease
    Lawitz, Eric
    Gane, Edward
    Cohen, Eric
    Vierling, John
    Agarwal, Kosh
    Hassanein, Tarek
    Mantry, Parvez S.
    Pockros, Paul J.
    Bennett, Michael
    Kemmer, Nyingi
    Morelli, Giuseppe
    Zha, Jiuhong
    Wang, Deli
    Shulman, Nancy S.
    Cohen, Daniel E.
    Reddy, K. Rajender
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (02): : 257 - 266
  • [7] Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C
    Flisiak, Robert
    Flisiak-Jackiewicz, Marta
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (06) : 559 - 567
  • [8] SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR plus DASABUVIR IN CHRONIC HEPATITIS C PATIENTS WITH HCV GENOTYPE 1 INFECTION
    Tatara, Tomasz
    Dabrowska-Bender, Marta
    Duda-Zalewska, Aneta
    Staniszewska, Anna
    ACTA POLONIAE PHARMACEUTICA, 2019, 76 (04): : 613 - 619
  • [9] Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection
    Johnson, Scott J.
    Parise, Helene
    Virabhak, Suchin
    Filipovic, Ivana
    Samp, Jennifer C.
    Misurski, Derek
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 983 - 994
  • [10] Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
    Smith, Michael A.
    Lim, Alice
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6083 - 6094
12345